Expanded Access Program of Dupilumab in Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy Who Have Been Previously Treated With Linvoseltamab and Background Dupilumab in the Parent Study R5458-668-ALG-2219 (NCT06369467)

Regeneron Pharmaceuticals

Status

Conditions: Food Allergy

Treatments: Drug: Dupilumab

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT06631677

R668-ALG-2448

Details and patient eligibility

About

This is an expanded access program of dupilumab that was never initiated and, therefore, not available.

Sex

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria